OrientSciences NewsPeptide and medical research from around the world, reported in English
7 min read
ObesityGLP-1China pharma

Is China's rival to tirzepatide now ahead of Lilly? What the ribupatide trial shows

China's own GIP/GLP-1 drug, not a copy of tirzepatide, cut weight 17.7% in 48 weeks, level with tirzepatide's 17.5% in China. What the JAMA paper shows.

For three years the question in obesity medicine has been how close anyone can get to Eli Lilly's tirzepatide. This week a Chinese company put a peer reviewed answer on the table. Hengrui Pharma's ribupatide, a once weekly injection that acts on the same two gut hormone receptors as tirzepatide, GLP-1 and GIP, cut body weight by 17.7 percent over 48 weeks in a phase 3 trial published online in JAMA on 15 November. To be clear, ribupatide is not a copy or a generic of tirzepatide. It is a different molecule that Hengrui discovered and developed itself, aimed at the same two targets. If anything the flow runs the other way: a US company, Kailera, has licensed the Chinese drug to develop it for the rest of the world.

That is almost exactly what tirzepatide's top dose achieved in China's own trial of the drug, 17.5 percent over 52 weeks, and weight loss on ribupatide had not clearly levelled off when the study ended. It is tempting to call that a win. The numbers support something more interesting and more precise: a Chinese molecule is now keeping pace with the market leader, and the open question is how much further it can go. The headline figures were first announced in July 2025. What the JAMA paper adds is peer review and the safety detail. We worked from trade coverage of the paper and the companies' releases, not the full text.

The trial

GEMINI-1 enrolled 567 adults with overweight or obesity and no diabetes at 55 sites in China between May and June 2024. They were randomised equally to ribupatide 2 mg, 4 mg or 6 mg, or placebo, once a week for 48 weeks, all alongside a lifestyle programme. Entry used Chinese thresholds, a BMI of 28 or more, or 24 or more with a weight related condition. The participants were young, with an average age of 34.4, and weighed 93 kg on average. Hengrui sponsored and ran the study.

The result

Average weight loss at week 48 was 10.7 percent on 2 mg, 16.4 percent on 4 mg and 17.7 percent on 6 mg, against 1.4 percent on placebo. Measured against placebo, the gaps were 9.3, 15.0 and 16.3 percentage points, all highly significant. At the two higher doses about three quarters of participants lost at least 10 percent of their weight, and 44.4 percent of those on 6 mg lost at least a fifth.

The gains went beyond the scales. Compared with placebo, waist circumference fell by between 6.4 and 11.8 cm across the doses. Systolic blood pressure fell by 7.1 to 8.7 mm Hg and HbA1c by 0.32 to 0.47 percentage points, although those last two analyses were not adjusted for multiple comparisons and should be read as supportive rather than proof.

Two ways of counting

Most coverage of this trial, and of obesity drugs generally, quotes a single number without saying how it was counted, and that hides a lot. Trials report weight loss in two ways. One counts everyone who was randomised, including people who stopped the drug or broke protocol. The other estimates what happens in people who stay on treatment as intended. The first is the more cautious figure. For ribupatide 6 mg it is the 17.7 percent in JAMA. On the second basis, Hengrui reported 19.2 percent.

The same split runs through every comparison people are making this week. Lilly's retatrutide, often quoted at 25.0 percent at 80 weeks on its top dose, reached 28.3 percent on the on treatment basis. Lining up a cautious number from one drug against an optimistic number from another can manufacture a gap that does not exist. Where we compare drugs below, we have tried to use like with like.

Next to tirzepatide

SURMOUNT-CN, Lilly's phase 3 trial of tirzepatide in Chinese adults, is the fairest yardstick because it tested a similar population against the same kind of threshold. In 210 adults over 52 weeks, tirzepatide 10 mg and 15 mg produced weight loss of 13.6 and 17.5 percent, against 2.3 percent on placebo, a gap of 15.1 points for the top dose. Ribupatide's top dose came out at 17.7 percent and 16.3 points, four weeks sooner.

On paper that is level, or a nose ahead. In practice it is too close to call. The trials were run years apart, in different people, by different companies, and SURMOUNT-CN had only 71 participants on its top dose. A difference of a fraction of a point between separate trials of this size is well inside the noise. What can fairly be said is that ribupatide is in the same league as tirzepatide in Chinese adults, and that a molecule discovered in China is now competing at the top of the class rather than following it.

What no plateau means

The most intriguing line in the paper is that weight loss at 4 mg and 6 mg had not clearly plateaued by week 48. That suggests the drug had more to give, but it is not a measurement of how much. There are clues. In an earlier Chinese phase 2 study, an 8 mg dose produced 23.6 percent weight loss at 36 weeks on the on treatment basis, again without a plateau. Hengrui's partner Kailera is now testing doses of up to 10 mg over 76 weeks, and a separate high dose phase 2b trial is due to report in mid 2027. Those are the results that will show whether ribupatide can move beyond tirzepatide rather than alongside it.

Safety

The side effect profile looks like the rest of the class. Gastrointestinal events, mostly diarrhoea, nausea and vomiting, affected 47.9, 58.2 and 63.1 percent of participants on the three doses, against 23.1 percent on placebo, and were mainly mild to moderate and concentrated during dose escalation. Only one or two people in each ribupatide group stopped permanently because of side effects. Serious adverse events ran at 1.4 to 5.0 percent on ribupatide against 5.6 percent on placebo. Three participants on ribupatide were diagnosed with papillary thyroid cancer, which investigators judged probably unrelated to treatment, and there were no cases of medullary thyroid cancer or acute pancreatitis.

China's obesity race

Ribupatide arrives in a market that has changed fast. Novo Nordisk's semaglutide lost patent protection in China on 20 March this year, and at least 10 weight loss injections and pills have been reported as lining up for Chinese approval in a market forecast to reach about 14 billion US dollars by 2030. Innovent's mazdutide, licensed from Lilly, became the first home grown obesity drug approved in China, and its higher 9 mg dose reported 18.55 percent weight loss at 60 weeks. Price competition is already fierce, with cuts of up to 80 percent reported earlier this year.

Hengrui, China's largest listed drug maker by revenue, filed ribupatide with the national regulator for long term weight management, and the application was accepted in November 2025. We found no report that it has been approved. A cardiovascular outcomes trial in people with atherosclerotic disease is under way.

The road outside China

Outside Greater China, ribupatide belongs to Kailera Therapeutics of Massachusetts, which licensed it from Hengrui in 2024 and raised 625 million US dollars in a Nasdaq listing in April. Its global phase 3 programme, KaiNETIC, has fully enrolled nearly 5,000 people across 11 countries, testing doses of up to 10 mg over 76 weeks, with results expected in mid 2028. One of the three trials includes an open label semaglutide 2.4 mg arm. None is a head to head trial against tirzepatide. A once daily oral version has also reported 12.1 percent weight loss at 26 weeks in China, and Kailera plans global phase 3 trials of the pill in the first half of 2027.

What is still unknown

The obvious gap is a direct comparison. Until ribupatide and tirzepatide are tested in the same trial, any ranking rests on cross trial comparisons, and the planned global trials compare against semaglutide, not tirzepatide. The participants in GEMINI-1 were young and all in China, so results in older adults and other populations will come from the global programme. Forty eight weeks is also short for a drug that would be taken for years, and how weight changes after treatment stops has not been reported.

Much of the detail sits in the full paper and its supplement, which we did not see. We do not yet know how the thyroid cases were assessed, how many people completed treatment, or how the higher doses being tested globally will be tolerated. OrientSciences worked from AJMC's report of the JAMA paper, the companies' releases and trade coverage, and did not read the full text.

SOURCES AND FURTHER READING

Share this update

Share this update: https://orientsciences.com/news/ribupatide-jama-china-tirzepatide-rival-hengrui-gemini-1

View all weekly news